Artiva Biotherapeutics price target raised to $23 from $18 at Wedbush

Wedbush raised the firm’s price target on Artiva Biotherapeutics (ARTV) to $23 from $18 and keeps an Outperform rating on the shares. The firm notes the company announced refractory rheumatoid arthritis as the lead indication for AlloNK and announced FDA Fast Track Designation, with pivotal development possible as early as 2026 pending regulatory discussions. Importantly, the development program will feature low-dose lymphodepletion to maximize B cell depletion while minimizing adverse impacts among this patient population.